Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in North America. In 2018, the first unified national guideline in Canada was developed for the front-line treatment of CLL that helped guide treat-ment across the country. As an update in 2022, a group of clinical experts from across Canada came together to provide input and guidance that included new and innovative treatments and approaches that will continue to provide health care professionals with clear guidance on the first-line management of CLL. Recommendations were provided in consensus based on available evidence for the first-line treatment of CLL.

Automated summary

In 2022, a group of clinical experts from Canada came together to provide new and innovative treatments and approaches for the first-line management of chronic lymphocytic leukemia (CLL), giving clear guidance for healthcare professionals.